 |
| AUGUST
4, 2025 |
| Covering
Life Sciences Drugs, Diagnostics, Devices,
Digital Health |
|
|
|
* may need subscription to view |
 |
| Boston's
most flexible contract vivarium
lab space: Start with a few study
cages and grow. |
|
Learn More
→ |
|
|
- Alveolus Bio: Secures Strategic Investment
From Shilpa Medicare to Advance Groundbreaking
Pulmonary Therapeutics More
- Dyne Therapeutics: FDA Breakthrough
Therapy Designation for DYNE-251 in Duchenne
Muscular Dystrophy (DMD) More
- Praxis Precision Medicines: Positive,
Best-in-Disease Topline Results in Patients
With Focal Onset Seizures From the RADIANT
Study of Vormatrigine More
|
|
 |
 |
Strategic
CFO Services for Biotech
Consider a fractional solution for
pre- and post IPO
financial support. |
|
Learn More
→ |
|
|
|
- Akebia Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Alnylam Soars Past $50B Market Cap More*
More
- Bruker: Second Quarter 2025 Financial
Results More
- Butterfly Network: Second Quarter 2025
Financial Results More
- Despite Ongoing Decline, Moderna’s Spikevax
Sales Beat Expectations in Q2 More
- enGene: Inducement Grants Under NASDAQ
Listing Rule 5635(c)(4) More
- HilleVax: Enters Into a Definitive
Agreement to be Acquired by XOMA Royalty for
$1.95 in Cash per Share Plus a Contingent
Value Right More
- KalVista Pharmaceuticals: Inducement Grants
Under Nasdaq Listing Rule 5635(c)(4) More
- NeuroSense: Business Update and Progress for
the First Half of 2025 More
- Prime Medicine: Closing of Public Offering
and Full Exercise of the Underwriters’ Option
to Purchase Additional Shares More
- Solid Biosciences: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Viridian Therapeutics: Inducement Grants
Under Nasdaq Listing Rule 5635(c)(4) More
- Waters: Second Quarter 2025 Financial
Results More
- Xenon Pharmaceuticals: Inducement Grants
Under Nasdaq Listing Rule 5635(c)(4) More
- Xilio Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
|
|
|
|
- After Strategic Reset, Amylyx Downsizes,
Moves Cambridge HQ More*
- After Surprise CRL, Replimune Says It’s
Waiting for FDA on a Path Forward for Cancer
Treatment More*
More*
- Biogen is Building a ‘'Ventures' Team To
'Keep Early Portfolio Externalized' More*
- Biotech Leaders Talk AI, Funding and Lab
Space at BBJ Event More*
- Moderna Preps Final Analysis of CMV Study,
Tacks On New Secondary Endpoints More*
- Subscribe to LifeSci Startup for
Updates on US Startups More
- The Top
Line: Untangling Sarepta’s Gene Therapy
Fallout and a Growing Trust Deficit Podcast
- UMass Amherst Marmoset Monkey Lab That Drew
PETA’s Ire Closes More*
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
Feature your company |
| Apply
to have your company
showcased by Big4Bio |
|
|
|
|
|
 |
|
Premier Executive Search and
Talent Advisory Firm Slone
Partners Launches Fractional
Talent Service to Deliver
On-Demand Leaders and Specialists
|
|
Learn More
→ |
|
|
- Feature: CEO's Perspective: The Power of
Pivoting More
- ICYMI: What Defines Great Leadership? More
- ICYMI: The Future of Hiring: How Fractional
Talent is Reshaping The Workforce More
- ICYMI:Beyond Cautious Optimism: Why a Hybrid
Talent Model is the Future for Life Sciences
& Healthcare More
- Reimagining Life Sciences Roles With AI and
Automation More
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2025
© 2025
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
